Related references
Note: Only part of the references are listed.Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families
Antoinette Hollestelle et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing
Paul D. P. Pharoah et al.
CLINICAL CANCER RESEARCH (2011)
MicroRNA let-7a: A potential marker for selection of paclitaxel in ovarian cancer management
Lingeng Lu et al.
GYNECOLOGIC ONCOLOGY (2011)
Evaluation of Kras Gene Mutation and Copy Number Gain in Non-small Cell Lung Cancer
Hidefumi Sasaki et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
A 3′-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis
Trupti Paranjape et al.
LANCET ONCOLOGY (2011)
miRNAs in the spotlight Making 'silent' mutations speak up
David W. Salzman et al.
NATURE MEDICINE (2011)
Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers
Aslaug Helland et al.
PLOS ONE (2011)
A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk
Elena Ratner et al.
CANCER RESEARCH (2010)
Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications
Delia Mezzanzanica et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2010)
MicroRNAs in ovarian cancer biology and therapy resistance
Marijn T. M. van Jaarsveld et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2010)
Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan
F. Graziano et al.
PHARMACOGENOMICS JOURNAL (2010)
Cancer Statistics, 2009
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
A Gene Expression Signature Associated with K-Ras Addiction Reveals Regulators of EMT and Tumor Cell Survival
Anurag Singh et al.
CANCER CELL (2009)
A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers
Brock C. Christensen et al.
CARCINOGENESIS (2009)
Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients
Ram Eitan et al.
GYNECOLOGIC ONCOLOGY (2009)
A SNP in a let-7 microRNA Complementary Site in the KRAS 3′ Untranslated Region Increases Non-Small Cell Lung Cancer Risk
Lena J. Chin et al.
CANCER RESEARCH (2008)
Polymorphisms in microRNA targets: a gold mine for molecular epidemiology
Kexin Chen et al.
CARCINOGENESIS (2008)
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer
Lin Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis
Lingeng Lu et al.
CANCER RESEARCH (2007)
MicroRNA signatures in human ovarian cancer
Marilena V. Iorio et al.
CANCER RESEARCH (2007)
Ovarian cancer: a focus on management of recurrent disease
Thomas J. Herzog et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer:: An intergroup trial of the AGO-OVAR, the NCICCTG, and the EORTC GCG
Jacobus Pfisterer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Oncomirs - microRNAs with a role in cancer
A Esquela-Kerscher et al.
NATURE REVIEWS CANCER (2006)
Genorne-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells
D Peters et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Oncogenic H-ras up-regulates expression of ERCCI to protect cells from platinum-based anticancer agents
CK Youn et al.
CANCER RESEARCH (2004)
Share Paper
